FLOLAN (epoprostenol sodium) for Injection is a sterile sodium salt formulated for intravenous (IV) administration. Each vial of FLOLAN contains epoprostenol sodium equivalent to either 0.5 mg (500,000 ng) or 1.5 mg (1,500,000 ng) epoprostenol, 3.76 mg glycine, 2.93 mg sodium chloride, and 50 mg mannitol. Sodium hydroxide may have been added to adjust pH.
FLOLAN is indicated for the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy (see CLINICAL TRIALS IN PULMONARY HYPERTENSION).
Media Articles Related to Flolan (Epoprostenol)
Targeted Therapies May Ease Severe Pulmonary Hypertension
Source: Medscape Critical Care Headlines [2015.09.29]
A new analysis has spotted a mortality reduction in patients with severe pulmonary hypertension caused by lung disease, but doubts remain.
Medscape Medical News
Pulmonary hypertension patients can safely benefit from exercise, review suggests
Source: Hypertension News From Medical News Today [2015.09.03]
Studies suggest exercise is safe and improves quality of life in patients with pulmonary hypertension - high blood pressure in the arteries between the heart and lungs.
Source: MedicineNet sildenafil Specialty [2015.02.19]
Title: Pulmonary Hypertension
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 2/19/2015 12:00:00 AM
Published Studies Related to Flolan (Epoprostenol)
IVI epoprostenol as salvage therapy in pulmonary arterial hypertension: an Australian perspective. [2011.03]
BACKGROUND: IVI epoprostenol is the only therapy for pulmonary arterial hypertension (PAH) with a randomized controlled trial demonstrating improved survival, when used as first-line monotherapy. In Australia it is used as salvage therapy for those failing treatment with other targeted therapies or presenting in World Health Organization functional class (FC) IV. AIMS: Report experience with IVI epoprostenol, administered as salvage therapy for the treatment of adults with PAH in a single Australian PAH centre... CONCLUSION: Findings support efficacy of epoprostenol as salvage therapy for patients with PAH. (c) 2011 The Authors. Internal Medicine Journal (c) 2011 Royal Australasian College of Physicians.
No effect of epoprostenol on right ventricular diameter in patients with acute pulmonary embolism: a randomized controlled trial. [2010.03.30]
BACKGROUND: Right ventricular dilatation in the setting of acute pulmonary embolism is associated with an adverse prognosis. Treatment with a pulmonary vasodilator has never been studied systematically. We evaluated the effect of epoprostenol on right ventricular diameter and function in patients with acute pulmonary embolism and right ventricular dilatation... CONCLUSION: In patients with acute pulmonary embolism and right ventricular overload, treatment with epoprostenol did not improve right ventricular dilatation or any other measured variables of right ventricular overload. TRIAL REGISTRATION: Registration: URL: NCT01014156Medical ethical committee: Medisch-ethische toetsingscommissie (METc) from the VUmc (free university medical centre).
Prostaglandin I2 (epoprostenol) triggers migraine-like attacks in migraineurs. [2010.02]
Prostacyclin [prostaglandin I(2) (PGI(2))] activates and sensitizes meningeal sensory afferents...
Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. [2008.10.21]
BACKGROUND: Oral sildenafil and intravenous epoprostenol have independently been shown to be effective in patients with pulmonary arterial hypertension. OBJECTIVE: To investigate the effect of adding oral sildenafil to long-term intravenous epoprostenol in patients with pulmonary arterial hypertension... CONCLUSION: In some patients with pulmonary arterial hypertension, the addition of sildenafil to long-term intravenous epoprostenol therapy improves exercise capacity, hemodynamic measurements, time to clinical worsening, and quality of life, but not Borg dyspnea score. Increased rates of headache and dyspepsia occurred with the addition of sildenafil.
Prostacyclin (epoprostenol) induces headache in healthy subjects. [2008.09.30]
The role of prostanoids in nociception is well established...
Clinical Trials Related to Flolan (Epoprostenol)
Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH) [Completed]
The purpose of this multicentre, open label, single-arm study in approximately 20 adult
patients is to evaluate the Impact on lifestyle of a new thermo stable formulation of
epoprostenol sodium in subjects with Pulmonary Arterial Hypertension (PAH).
Effects of Prostacyclin Infusion on Cerebral Vessels and Metabolism in Patients With Subarachnoid Haemorrhage [Completed]
The purpose of this study is to determine whether prostacyclin is effective in prevention of
cerebral vasospasm in patients with subarachnoidal hemorrhage (SAH).
Prostacyclin's Effect on Platelet Responsiveness [Completed]
Inhaled Nitric Oxide and Inhaled Prostacyclin After Cardiac Surgery for Heart Transplant or LVAD Placement [Recruiting]
Research study evaluating the individual and combined effects of inhaled medications, nitric
oxide and prostacyclin, on the function of the right heart after surgery for either heart
transplant or for left ventricular assist device (LVAD) placement. The investigators hope to
learn if these two medications, when given together after surgery, improve right heart
function by lowering blood vessel pressures in the lungs. The investigators hope to learn if
the combined effects of these two medications are better than either medication used alone.
Participants were selected as a possible participant in this study because right heart
problems are common during and after surgery for heart transplant and for LVAD placement. In
addition, the inhaled medication, nitric oxide, is always given during and after these two
types of surgeries at Stanford to help improve how the right heart functions.
Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Open Heart Surgery [Terminated]
Endothelin-1 is a powerful substance that may be involved in causing hemodynamic instability
(problems related to unstable blood pressure) during and after open heart surgery.
Tezosentan is an investigational intravenous drug that blocks the endothelin receptors.
This clinical trial will assess the potential benefit of tezosentan compared with placebo in
the treatment of patients undergoing open heart surgery with cardiopulmonary bypass (CPB).
Treatment time is from the start of surgery up to 24 hours.
Reports of Suspected Flolan (Epoprostenol) Side Effects
Device Related Infection (32),
Pain in JAW (31),
Oedema Peripheral (29), more >>